Your browser doesn't support javascript.
Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: In Vitro Activity against SARS-CoV-2 and Potential Mechanisms.
Puhl, Ana C; Fritch, Ethan J; Lane, Thomas R; Tse, Longping V; Yount, Boyd L; Sacramento, Carolina Q; Fintelman-Rodrigues, Natalia; Tavella, Tatyana Almeida; Maranhão Costa, Fabio Trindade; Weston, Stuart; Logue, James; Frieman, Matthew; Premkumar, Lakshmanane; Pearce, Kenneth H; Hurst, Brett L; Andrade, Carolina Horta; Levi, James A; Johnson, Nicole J; Kisthardt, Samantha C; Scholle, Frank; Souza, Thiago Moreno L; Moorman, Nathaniel John; Baric, Ralph S; Madrid, Peter B; Ekins, Sean.
  • Puhl AC; Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, North Carolina 27606, United States.
  • Fritch EJ; Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, United States.
  • Lane TR; Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, North Carolina 27606, United States.
  • Tse LV; Department of Epidemiology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, United States.
  • Yount BL; Department of Epidemiology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, United States.
  • Sacramento CQ; Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil.
  • Fintelman-Rodrigues N; Centro De Desenvolvimento Tecnológico Em Saúde (CDTS), Fiocruz, Rio de Janeiro 21040-900, Brazil.
  • Tavella TA; Laboratório de Imunofarmacologia, Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ 21040-900, Brazil.
  • Maranhão Costa FT; Centro De Desenvolvimento Tecnológico Em Saúde (CDTS), Fiocruz, Rio de Janeiro 21040-900, Brazil.
  • Weston S; Laboratory of Tropical Diseases-Prof. Dr. Luiz Jacinto da Silva, Department of Genetics, Evolution, Microbiology and Immunology, University of Campinas-UNICAMP, Campinas, São Paulo 13083-970, Brazil.
  • Logue J; Laboratory of Tropical Diseases-Prof. Dr. Luiz Jacinto da Silva, Department of Genetics, Evolution, Microbiology and Immunology, University of Campinas-UNICAMP, Campinas, São Paulo 13083-970, Brazil.
  • Frieman M; Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States.
  • Premkumar L; Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States.
  • Pearce KH; Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States.
  • Hurst BL; Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, United States.
  • Andrade CH; Center for Integrative Chemical Biology and Drug Discovery, Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, United States.
  • Levi JA; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599, United States.
  • Johnson NJ; Institute for Antiviral Research, Utah State University, Logan, Utah 84322, United States.
  • Kisthardt SC; Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, Utah 84322, United States.
  • Scholle F; Laboratory of Tropical Diseases-Prof. Dr. Luiz Jacinto da Silva, Department of Genetics, Evolution, Microbiology and Immunology, University of Campinas-UNICAMP, Campinas, São Paulo 13083-970, Brazil.
  • Souza TML; LabMol-Laboratory of Molecular Modeling and Drug Design, Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia, GO 74605-170, Brazil.
  • Moorman NJ; Department of Biological Sciences, North Carolina State University, Raleigh, North Carolina 27695, United States.
  • Baric RS; Department of Biological Sciences, North Carolina State University, Raleigh, North Carolina 27695, United States.
  • Madrid PB; Department of Biological Sciences, North Carolina State University, Raleigh, North Carolina 27695, United States.
  • Ekins S; Department of Biological Sciences, North Carolina State University, Raleigh, North Carolina 27695, United States.
ACS Omega ; 6(11): 7454-7468, 2021 Mar 23.
Article in English | MEDLINE | ID: covidwho-1155692
ABSTRACT
Severe acute respiratory coronavirus 2 (SARS-CoV-2) is a newly identified virus that has resulted in over 2.5 million deaths globally and over 116 million cases globally in March, 2021. Small-molecule inhibitors that reverse disease severity have proven difficult to discover. One of the key approaches that has been widely applied in an effort to speed up the translation of drugs is drug repurposing. A few drugs have shown in vitro activity against Ebola viruses and demonstrated activity against SARS-CoV-2 in vivo. Most notably, the RNA polymerase targeting remdesivir demonstrated activity in vitro and efficacy in the early stage of the disease in humans. Testing other small-molecule drugs that are active against Ebola viruses (EBOVs) would appear a reasonable strategy to evaluate their potential for SARS-CoV-2. We have previously repurposed pyronaridine, tilorone, and quinacrine (from malaria, influenza, and antiprotozoal uses, respectively) as inhibitors of Ebola and Marburg viruses in vitro in HeLa cells and mouse-adapted EBOV in mice in vivo. We have now tested these three drugs in various cell lines (VeroE6, Vero76, Caco-2, Calu-3, A549-ACE2, HUH-7, and monocytes) infected with SARS-CoV-2 as well as other viruses (including MHV and HCoV 229E). The compilation of these results indicated considerable variability in antiviral activity observed across cell lines. We found that tilorone and pyronaridine inhibited the virus replication in A549-ACE2 cells with IC50 values of 180 nM and IC50 198 nM, respectively. We used microscale thermophoresis to test the binding of these molecules to the spike protein, and tilorone and pyronaridine bind to the spike receptor binding domain protein with K d values of 339 and 647 nM, respectively. Human Cmax for pyronaridine and quinacrine is greater than the IC50 observed in A549-ACE2 cells. We also provide novel insights into the mechanism of these compounds which is likely lysosomotropic.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Language: English Journal: ACS Omega Year: 2021 Document Type: Article Affiliation country: Acsomega.0c05996

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Language: English Journal: ACS Omega Year: 2021 Document Type: Article Affiliation country: Acsomega.0c05996